Form 4: Ultragenyx Director Shehnaaz Suliman Reports Equity Activity
Statement of Changes in Beneficial Ownership
Director Shehnaaz Suliman acquired restricted stock units and stock options while selling a portion of common stock holdings.
Summary
- Director Shehnaaz Suliman received an award of 7,751 Restricted Stock Units (RSUs) on May 14, 2026.
- Director Suliman was granted 14,058 stock options with an exercise price of $25.80 on May 14, 2026.
- The director sold 5,740 shares of common stock at a price of $25.12 per share on May 18, 2026.
- Following these transactions, the director holds 27,951 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event; the acquisition of equity is offset by the sale of shares, and the activity is consistent with routine director compensation and pre-planned trading.
Positives
- Director compensation via equity aligns interests with long-term shareholder value.
- The RSU and option grants vest within one year, indicating a commitment to the company's near-term performance.
Negatives
- The sale of 5,740 shares reduces the director's direct equity stake in the company.
Risks
- Market volatility could impact the value of the granted options if the stock price remains below the $25.80 exercise price.
Future Outlook
The equity awards are set to vest on the earlier of the next Annual Meeting of Stockholders or May 14, 2027, aligning director incentives with the company's upcoming annual cycle.
Management Comments
- The transactions were executed pursuant to a Rule 10b5-1(c) trading plan.
Industry Context
StockSavvy.ai notes that director equity activity in the biotechnology sector is standard practice for compensation, though 10b5-1 plans are frequently used to mitigate concerns regarding insider trading optics.
Comparison to Industry Standards
- The use of 10b5-1 plans is a best-practice standard for corporate governance in the U.S. biotech industry.
- Equity-based compensation for board members is consistent with peer companies like BioMarin or Sarepta Therapeutics.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Plan Utilization | Grant of equity under the 2023 Incentive Plan. | 05/14/2026 | Standard compensation practice. |
Stakeholder Impact
- Shareholders should view this as routine director compensation activity.
Next Steps
- Vesting of RSUs and options on or before May 14, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Grant date for RSUs and stock options. |
| 05/18/2026 | Date of common stock sale and filing date. |
| 05/14/2027 | Vesting date for RSUs and stock options. |
Keywords
Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Director Transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.